Genix Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Revenue	-	0	0.01	-	-
Revenue Growth (YoY)	-	-67.19%	-	-	-
Cost of Revenue	-	0.18	0.01	-	0
Gross Profit	-	-0.18	0	-	-0
Selling, General & Admin	0.12	0.15	0.23	0.18	0.26
Amortization of Goodwill & Intangibles	0	0	0.54	0.54	0.52
Operating Expenses	0.13	0.18	0.84	1	1.61
Operating Income	-0.13	-0.36	-0.83	-1	-1.61
Interest Expense	-0.17	-0.12	-0.05	-0.01	-0
Interest & Investment Income	0	0	0	0	0
Currency Exchange Gain (Loss)	-0	-0	-0.01	-0.03	0
Other Non Operating Income (Expenses)	-0.03	-0.06	-0.05	-0.03	-0.05
EBT Excluding Unusual Items	-0.33	-0.55	-0.94	-1.07	-1.65
Asset Writedown	-0.01	-	-3.46	-	-
Other Unusual Items	-	0.47	-	-	-
Pretax Income	-0.34	-0.07	-4.4	-1.07	-1.65
Earnings From Continuing Operations	-0.34	-0.07	-4.4	-1.07	-1.65
Net Income	-0.34	-0.07	-4.4	-1.07	-1.65
Net Income to Common	-0.34	-0.07	-4.4	-1.07	-1.65
Shares Outstanding (Basic)	60	59	59	59	59
Shares Outstanding (Diluted)	60	59	59	59	59
Shares Change (YoY)	0.54%	-	-	-	18.55%
EPS (Basic)	-0.01	-0.00	-0.07	-0.02	-0.03
EPS (Diluted)	-0.01	-0.00	-0.07	-0.02	-0.03
Free Cash Flow	-0.12	-0.19	-0.22	-0.22	-0.43
Free Cash Flow Per Share	-0.00	-0.00	-0.00	-0.00	-0.01
Gross Margin	-	-	26.43%	-	-
Operating Margin	-	-8986.67%	-6737.05%	-	-
Profit Margin	-	-1806.86%	-35600.34%	-	-
Free Cash Flow Margin	-	-4624.54%	-1787.27%	-	-
EBITDA	-0.12	-0.36	-0.29	-0.46	-1.09
D&A For EBITDA	0	0	0.55	0.54	0.52
EBIT	-0.13	-0.36	-0.83	-1	-1.61
Revenue as Reported	-	0	0.01	-	-

Updated Oct 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.